Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

IDEC-Y2B8/rituximab combination enters phase III

Feb. 27, 1998

UCSF receives green light to develop new breast cancer therapy

Feb. 24, 1998

Maxamine progresses to phase III in AML

Feb. 23, 1998

Phase I trial results of DAB389IL-2 in lymphoma

Feb. 20, 1998

Seragen fusion toxin will get priority review

Feb. 5, 1998

Anti-ErbB3 antibodies described by Genentech in patent literature

Feb. 3, 1998

Proleukin cleared for marketing in U.S. for melanoma indication

Jan. 30, 1998

AltaRex reacquires Western European marketing rights to Ovarex

Jan. 27, 1998

New approach to cancer therapy reported

Jan. 27, 1998

Vical receives patent protection for lipid-mediated DNA vaccines

Jan. 8, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...